Cell Therapeutics, Inc. (CTI) Readies Pixuvri European Launch and Start of Pacritinib Phase 3 Trial; Reports Second Quarter Financial Results and Milestones Full Text
Cell Therapeutics, 08/03/2012
For the quarter ended, total operating expenses were $49.4 million compared to $16.9 million for the same period in 2011. The increase is predominantly due to an acquired in–process research and development expense of $29.1 million relating primarily to the acquisition of pacritinib from S*BIO Pte Ltd. in addition to equity–based compensation and expenses related to preparation for commercialization of Pixuvri in the E.U.



